Tools for Practice Outils pour la pratique

#340 Crying babies: Can proton pump inhibitors help?

In infants (≤1year) with crying/irritability attributed to feeds, do proton pump inhibitors (PPIs) improve symptoms over placebo without additional harms?

PPIs do not improve crying, fussiness, irritability, or regurgitation attributed to feeds. However, PPIs may increase the risk of serious adverse effects (e.g., respiratory tract infections) from 2.5% on placebo to 12% at 4 weeks.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Results statistically significant unless indicated. Randomized, controlled trials (RCTs) on infants retrieved from systematic reviews in the last ten years since no meta-analyses available.1-5
  • Two placebo-controlled RCTs of PPIs; four-week duration:6,7
    • 162 infants (median age: 4 months) crying within 1 hour of ≥25% of feeds; lansoprazole (0.2-1.5mg/kg/day):6
      • ≥50% reduction in feedings with crying episode(s)/duration of episodes: 54% in each group.
      • Crying, regurgitations, stopped feedings, feed refusal, back arching: No differences.
      • Serious adverse events (e.g., respiratory tract infections): 12% versus 2.5% (placebo), number needed to harm (NNH)=10.
    • 30 infants (mean age: 5 months) with frequent crying and reflux confirmed on biopsy/pH monitoring; omeprazole (10-20mg/day):7
      • Crying/fussing (minutes/24 hours): No difference.
      • Irritability (0-10 visual analogue score, lower=better): No difference.
  • No placebo-controlled RCTs of histamine-2 receptor antagonists.
    • Head-to-head comparisons versus PPI: No difference.8
  • Four withdrawal RCTs (8-268 infants, 1-11 months): Open-label treatment with rabeprazole,9 esomeprazole,10 pantoprazole,11 or famotidine12 x 1-4 weeks; responders/compliers randomized to blinded continued drug or placebo. At 4-5 weeks:
    • Vomiting, regurgitation, irritability, feeding difficulties, symptoms scores, adverse effects: No differences.9-11
    • Weight: No difference.9
  • Limitations: Most RCTs industry funded.6,9-12

  • Frequent effortless regurgitation of feeds is common in early infancy (affecting ≥40%).13
  • Regurgitation accompanied by distress symptoms (e.g., crying, back arching, irritability) have traditionally been attributed to gastroesophageal reflux disease. While PPIs improve esophageal pH in infant RCTs,7 they do not improve symptoms.
  • Guidelines recommend against empiric trials of acid-suppressing drugs for crying/distress or regurgitation.13,14 Parents can be reassured that frequent regurgitation can be normal and frequently settles (90% have resolution at age ≤1 year).13

Gilbert Bretecher May 29, 2023

no benefit to PPI’s

Greg Sherman February 1, 2024

reinforces regurg very common and PPI actually harm

Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Omar Abo Saada PharmD Candidate
  • Émélie Braschi MD PhD
  • Samantha S. Moe PharmD

1. Tighe M, Afzal NA, Bevan A, et al. Cochrane Database Syst Rev. 2014; (11).

2. van der Pol R, Langendam M, Benninga M, et al. JAMA Pediatr. 2014; 168(10),947-954.

3. Cohen S, Bueno de Mesquita M, Mimouni FB. Br J Clin Pharmacol. 2015; 80(2),200-208

4. Gieruszczak-Białek D, Konarska Z, Skórka A, et al. J Pediatr. 2015; 166(3),767-770.

5. Mattos AZD, Marchese GM, Fonseca BB, et al. Arq Gastroenterol. 2017; 54,271-280.

6. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. J Pediatr. 2009; 154(4),514-520.

7. Moore DJ, Tao BSK, Lines DR, et al. J Pediatr. 2003; 143(2),219-223.

8. Azizollahi HR, Rafeey M. Korean J Pediatr. 2016; 59(5),226.

9. Hussain S, Kierkus J, Hu P, et al. J Pediatr Gastroenterol Nutr. 2014; 58(2),226-236.

10. Winter H, Gunasekaran T, Tolia V, et al. J Pediatr Gastroenterol Nutr. 2015; 60,S9-S15.

11. Winter H, Kum-Nji P, Mahomedy SH, et al. J Pediatr Gastroenterol Nutr. 2010; 50(6),609-618.

12. Orenstein SR, Shalaby TM, Devandry SN, et al. Aliment Pharmacol Ther. 2003; 17(9),1097-1107.

13. Rosen R, Vandenplas Y, Singendonk M, et al. J Pediatr Gastroenterol Nutr. 2018; 66(3),516.

14. Davies I, Burman-Roy S, Murphy MS. BMJ. 2015; 350.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.